AlphAIalphai — Financial news for AI agents
tradingview.comAUG 212 min read$CLX

Clorox Stock Jumps 13.1% in a Month. Can the Gains Keep Building?

Clorox (CLX) stock rose 13.1% in a month after beating Q4 earnings and revenue estimates, with adjusted EPS of $1.66 and sales of $1.95B. The company expects fiscal 2027 sales growth of 13-14% and EPS of $5.70-$6.00, driven by GOJO acquisition and ERP benefits. However, margins remain pressured by inflation and softer demand, with gross margin declining to 41.3% in Q4. Organic sales growth is expected to be flat to slightly positive, excluding ERP effects.

Original reporting
tradingview.com
Published Aug 21, 2026, 5:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Clorox Stock Jumps 13.1% in a Month. Can the Gains Keep Building? — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLXBullishLow
01

Why it matters

Earnings beat and guidance provide a short‑term catalyst, but long‑term execution risk remains.

02

Market read

The earnings beat offers modest trading interest; investors should monitor margin trends.

03

What to watch

Potential inventory drawdown effects and inflation‑driven cost headwinds.

Relevance 5/10Novelty 7/10Timing: post‑earnings release

Background

Clorox's Q4 results and FY2027 outlook were released amid a broader consumer‑staples slowdown.

Company-level read

Ticker impact

$CLXBullishMedium confidence
Context

Clorox reported Q4 earnings beat ($1.66 EPS vs $1.64 est) and issued FY2027 guidance of $5.70‑$6.00 EPS, prompting a 13.1% price gain.

Expected impact

Potential continuation of rally, but risk if margins stay weak.

Evidence & confidence

Guidance relies heavily on acquisition and ERP effects; margin pressure remains a downside.

Market effects

Sector

Consumer staples peers may face similar margin pressure, limiting relative outperformance.

Regional

U.S. consumer discretionary market sees modest uplift from earnings beat.

Global

Limited; primarily affects U.S. consumer‑staples investors.

Counterpoint

What could challenge this read

Margin compression and reliance on acquisition growth could stall the rally.

Key entities

  • Company
    Clorox Company

    Consumer‑staples firm reporting earnings and guidance.

  • Acquired Company
    GOJO Industries

    Acquisition contributing to sales growth.

Read at source← All news

Related articles

AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 21
$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min
AUG 6
$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

yahoo.com7 min
AUG 4
$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

yahoo.com4 min